These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 24697920)
1. Hepatitis C virus NS3 mutations in haemophiliacs. Lin MV; Charlton AN; Rouster SD; Zamor PJ; Sherman KE Haemophilia; 2014 Sep; 20(5):659-65. PubMed ID: 24697920 [TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV. Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798 [TBL] [Abstract][Full Text] [Related]
4. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932 [TBL] [Abstract][Full Text] [Related]
5. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection. Lisboa-Neto G; Noble CF; Pinho JR; Malta FM; Gomes-Gouvêa MS; Alvarado-Mora MV; da Silva MH; Leite AG; Piccoli LZ; Rodrigues FK; Carrilho FJ; Mendes-Correa MC Antivir Ther; 2015; 20(3):281-7. PubMed ID: 25279715 [TBL] [Abstract][Full Text] [Related]
6. Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy. Abdel-Hameed EA; Rouster SD; Ji H; Ulm A; Hetta HF; Anwar N; Sherman KE; Shata MT Viral Immunol; 2016 May; 29(4):252-8. PubMed ID: 26885675 [TBL] [Abstract][Full Text] [Related]
7. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1]. Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862 [TBL] [Abstract][Full Text] [Related]
9. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China. Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031 [TBL] [Abstract][Full Text] [Related]
10. Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba. Andonov A; Kadkhoda K; Osiowy C; Kaita K Can J Gastroenterol; 2013 Jul; 27(7):414-6. PubMed ID: 23862174 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of Naturally Occurring Resistance Associated Substitutions in NS3/4AProtease Inhibitors in Iranian HCV/HIV Infected Patients. Baesi K; Velayati AA; Ashtiani MF; Fakhredini K; Banifazl M; Larijani MS; Basimi P; Ramezani A Curr HIV Res; 2021; 19(5):391-397. PubMed ID: 34238162 [TBL] [Abstract][Full Text] [Related]
12. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Hoffmann L; Ramos JA; Souza EV; Araújo Ramos AL; Villela-Nogueira CA; Urményi TP; Tanuri A; Rondinelli E; Silva R Virol J; 2013 Feb; 10():57. PubMed ID: 23409973 [TBL] [Abstract][Full Text] [Related]
13. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. Cento V; Mirabelli C; Salpini R; Dimonte S; Artese A; Costa G; Mercurio F; Svicher V; Parrotta L; Bertoli A; Ciotti M; Di Paolo D; Sarrecchia C; Andreoni M; Alcaro S; Angelico M; Perno CF; Ceccherini-Silberstein F PLoS One; 2012; 7(7):e39652. PubMed ID: 22792183 [TBL] [Abstract][Full Text] [Related]
14. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients. Aparicio E; Franco S; Parera M; Andrés C; Tural C; Clotet B; Martínez MA J Virol; 2011 Jun; 85(12):5961-9. PubMed ID: 21471227 [TBL] [Abstract][Full Text] [Related]
15. Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan. Ogishi M; Yotsuyanagi H; Tsutsumi T; Gatanaga H; Ode H; Sugiura W; Moriya K; Oka S; Kimura S; Koike K PLoS One; 2015; 10(3):e0119145. PubMed ID: 25748426 [TBL] [Abstract][Full Text] [Related]
16. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus. Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206 [No Abstract] [Full Text] [Related]
17. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845 [TBL] [Abstract][Full Text] [Related]
18. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481 [TBL] [Abstract][Full Text] [Related]
19. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients. Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900 [TBL] [Abstract][Full Text] [Related]
20. Use of next-generation sequencing in the CHAT study (acute HCV in HIV): effect of baseline resistance-associated NS3 variants on treatment failure. Jagjit Singh GK; Kaye S; Abbott JC; Boesecke C; Rockstroh J; McClure MO; Nelson M HIV Clin Trials; 2018 Apr; 19(2):46-51. PubMed ID: 29493385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]